基于泛癌样本分析CDS1在乳腺癌中的表达及预后预测价值

doi:10.3969/j.issn.1004-616x.2025.05.005

Abstract

Abstract: OBJECTIVE：This study aimed to explore relationships between CDP-diacylglycerol synthase 1 (CDS1) and various cancers through bioinformatics analysis， and to further validate expression and prognostic value of CDS1 in breast cancer viain vitro experiments. METHODS：Using RNA sequencing (RNA-seq) data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO)，expression patterns and prognostic value of CDS1 in various cancer types were systematically analyzed. Relationships between CDS1 expression and immune subtypes were further investigated. Functional enrichment analysis of differentially expressed genes in breast cancer was performed，and a gene co-expression network was constructed. Immunohistochemistry (IHC) was used to detect differences in CDS1 protein expression levels between normal and cancerous tissues in breast cancer patients (BRCA). Lastly， a survival prediction nomogram model incorporating CDS1 expression was constructed and validated. RESULTS： Compared with adjacent non-tumorous tissues， CDS1 exhibited significantly higher expression in multiple cancer tissues (P <0.05). Importantly，breast cancer patients with high CDS1 expression demonstrated a significantly shorter recurrence-free survival (P <0.01). Furthermore， CDS1 expression differed significantly across breast cancer immune-histochemical subtypes (P <0.01). Functional enrichment analysis suggested that CDS1 was involved in the lipid metabolism regulatory pathway and the PI3K-Akt signaling pathway. Correlation analysis revealed significant associations between CDS1 expression and expression of PIK3CA (r=0.415， P <0.01) and ERBB2 (r=0.361， P <0.01). IHC results confirmed that CDS1 expression was significantly elevated in breast cancer tissues compared to adjacent tissues (P <0.01)， and correlated with shorter overall survival in patients with high expression (P <0.05). Additionally， HER-2 expression showed significant variations among breast cancer patients with different CDS1 expression levels (χ²= 6.176， p=0.013). The constructed nomogram exhibited good predictive performance for survival (concordance index=0.746， p=0.018). CONCLUSION： CDS1 was highly expressed in breast cancer and was significantly correlated with HER-2 expression， making it a valuable prognostic biomarker. Its potential role in lipid metabolism and the PI3K-Akt signaling pathway suggests that CDS1 contributed to breast cancer progression. The constructed nomogram model incorporating CDS1 expression provides an effective tool for survival prediction in breast cancer patients.

Key words: CDS1, pan-cancer analysis, breast cancer, bioinformatics, prognosis

CLC Number:

R737.9

LI Jiarong, LIN Junhao, QIU Zhaolong, ZHU Zhiqin, CHEN Fengsheng. Expression and prognostic value of CDS1 in breast cancer based on pan-cancer analysis[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2025, 37(5): 375-382.

References

[1] BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263.
[2] ADAMS S C, NAMBIAR A K, BRESSLER E M, et al. Immunotherapies for locally aggressive cancers[J]. Adv Drug Deliv Rev, 2024, 210: 115331.
[3] YE F, DEWANJEE S, LI Y H, et al. Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer [J]. Mol Cancer, 2023, 22(1): 105.
[4] MAAN M, PETERS J M, DUTTA M, et al. Lipid metabolism and lipophagy in cancer[J]. Biochem Biophys Res Commun, 2018, 504(3): 582-589.
[5] MUKHERJEE A, BILECZ A J, LENGYEL E. The adipocyte microenvironment and cancer[J]. Cancer Metastasis Rev, 2022, 41(3): 575-587.
[6] D’SOUZA K, KIM Y J, BALLA T, et al. Distinct properties of the two isoforms of CDP-diacylglycerol synthase[J]. Biochemistry, 2014, 53(47): 7358-7367.
[7] INGLIS-BROADGATE S L, OCAKA L, BANERJEE R, et al. Isolation and characterization of murine Cds (CDP-diacylglycerol synthase) 1 and 2[J]. Gene, 2005, 356: 19-31.
[8] XU Y Q, MAK H Y, LUKMANTARA I, et al. CDP-DAG synthase 1 and 2 regulate lipid droplet growth through distinct mechanisms[J]. J Biol Chem, 2019, 294(45): 16740-16755.
[9] YEH K T, TANG K P, CHEN Y L, et al. Methylation inactivates expression of CDP-diacylglycerol synthase 1(CDS1) in hepatocellular carcinoma[J]. Cancer Genomics Proteomics, 2006, 3(3/4): 231-238.
[10] LI T W, FAN J Y, WANG B B, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells[J]. Cancer Res, 2017, 77(21): e108-e110.
[11] TANG Z F, KANG B X, LI C W, et al. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis[J]. Nucleic Acids Res, 2019, 47(W1): 556-560.
[12] WU C L, JIN X F, TSUENG G, et al. BioGPS: building your own mash-up of gene annotations and expression profiles[J]. Nucleic Acids Res, 2016, 44(D1): D313-D316.
[13] ZHOU G Y, SOUFAN O, EWALD J, et al. NetworkAnalyst 3.0: a visual analytics platform for comprehensive gene expression profiling and meta-analysis[J]. Nucleic Acids Res, 2019, 47(W1): 234-241.
[14] MAGAKI S, HOJAT S A, WEI B W, et al. An introduction to the performance of immunohistochemistry[J]. Methods Mol Biol, 2019, 1897: 289-298.
[15] RU B B, WONG C N, TONG Y, et al. TISIDB: an integrated repository portal for tumor-immune system interactions[J]. Bioinformatics, 2019, 35(20): 4200-4202.
[16] EPAND R M. Features of the phosphatidylinositol cycle and its role in signal transduction[J]. J Membr Biol, 2017, 250(4): 353-366.
[17] BLUNSOM N J, COCKCROFT S. Phosphatidylinositol synthesis at the endoplasmic reticulum[J]. Biochim Biophys Acta Mol Cell Biol Lipids, 2020, 1865(1): 158471.
[18] EPPENBERGER-CASTORI S, KLINGBIEL D, RUHSTALLER T, et al. Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: results of a randomized study - SAKK 22/99[J]. BMC Cancer, 2020, 20(1): 114.
[19] ZHONG X Y, ZENG C T, HU S L, et al. CDP-diacylglycerol synthase 1 promotes proliferation, invasion, and metastasis in hepatocellular carcinoma[J]. J Biol Regul Homeost Agents, 2024, 38(1): 573-584.
[20] BROWNE I M, OKINES A F C. Resistance to targeted inhibitors of the PI3K/AKT/mTOR pathway in advanced oestrogenreceptor-positive breast cancer[J]. Cancers, 2024, 16(12): 2259.
[21] SCHLAM I, TARANTINO P, TOLANEY S M. Overcoming resistance to HER2-directed therapies in breast cancer[J]. Cancers, 2022, 14(16): 3996.
[22] SWAIN S M, MILES D, KIM S B, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study [J]. Lancet Oncol, 2020, 21(4): 519-530.
[23] CORTES J, RUGO H S, CESCON D W, et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer [J]. N Engl J Med, 2022, 387(3): 217-226.
[24] SCHMID P, CORTES J, DENT R, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer[J]. N Engl J Med, 2022, 386(6): 556-567.
[25] CARDOSO F, O??SHAUGHNESSY, LIU Z Z, et al. Pembrolizumab and chemotherapy in high-risk, early-stage, ER(+)/HER2(-) breast cancer: a randomized phase 3 trial[J]. Nat Med, 2025, 31(2): 442-448.
[26] SCHLAM I, CORTI C, SAMMONS S, et al. Checkpoint inhibition for early-stage hormone receptor-positive breast cancer[J]. Expert Opin Biol Ther, 2024, 24(6): 511-520.

Expression and prognostic value of CDS1 in breast cancer based on pan-cancer analysis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	GUO Ai, HUANG Ning, ZHANG Jing, ZHANG Yuanyuan, AN Jusheng, LIU Mei. Expression of RUNX family transcription factor 1 and its prognostic value in cervical adenocarcinomas [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2025, 37(3): 190-195.
[2]	JI Jie, MA Sheng, HUANG Guiwen, XIAO Ting. Expression and clinical significance of marker cofilin-1 in low-abundance proteome from plasma of lung adenocarcinoma patients [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2025, 37(3): 202-208.
[3]	CAI Zeman, GUO Haipeng, LI Huier, LIN Yiwei, WU Fangcai, KANG Weipiao. A nomogram based on clinical characteristics and serological indicators for prognosis prediction of surgical tongue squamous cell carcinomas [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2025, 37(3): 234-241,261.
[4]	HOU Huiyun, BAI Feihu, YAN Xi, WU Lihong, ZUO Pengxi, WANG Jun. Correlations between COL5A2 protein expression and clinicopathological parameters in patients with gastric cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2025, 37(3): 242-247.
[5]	YU Pingyang, LI Jinyang, DOU He, XIAO Min. Glycyrrhizic acid reduces paclitaxel resistance in triple-negative breast cancer by inhibiting the OGT-MDH1 signaling pathway [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2025, 37(1): 33-38.
[6]	Lü Jie, CHEN Zhonghua, WANG Bo. The role of circular RNA homeodomain interacting protein kinase 3 in triple-negative breast cancer cell invasion [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2025, 37(1): 39-44,51.
[7]	LU Wanyao, LIU Yining, SHABAHAITI·Wusiman, AI Leyu, HU Xiaowen, LI Jinglei, ZHONG Xuanyu, AIMIRELA·Mierkadier, YI Na, LIU Ling. Differential expression of copper death related gene COX17 in esophageal carcinoma and its effect on Eca109 cell function [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2025, 37(1): 45-51.
[8]	XIAO Huanqin, XIE Shoucheng, ZHONG Ying, LUO Wenjuan, HUANG Yanfang, LUO Haiyan, YU Qiuzhu, ZHU Wenbiao. ZMYND8 as a novel diagnostic and prognostic biomarker for glioma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2025, 37(1): 52-55,62.
[9]	YANG Yihui, ZHANG Wenxia, GONG Zhining, CEN Xuexue, QIN Qimin, TANG Hongping. Clinicopathological characterization of HER-2-low cases among breast cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(6): 457-462.
[10]	GUO Xujuan, JIA Yuming, YAN Xi, ZHAO Hongzheng, GUO Yiyang, ZHANG Jinyan. Clinical value of CST4 in auxiliary diagnosis and prognosis assessment of pancreatic cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(6): 463-469.
[11]	KANG Xiaopei, GUO Zhenjiang, LIU Fangzhen. The expression and prognosis of BAF57 in colorectal cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(5): 379-383.
[12]	WU Mengyu, DE Xiaoming, SHAN Jing, LI Jie, ZHANG Yingchi, XU Haiming. Effect of silica exposure on gene expression in respiratory epithelium [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(4): 268-274,280.
[13]	ZHU Wenbiao, YAN Chunmei, QIU Bo, XIE Shoucheng, XIAO Huanqin, LIU Gaomin. Expression of secreted frizzled-related protein 4 in hepatocellular carcinoma, and relationship with clinicopathological index and prognosis [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(4): 288-293,297.
[14]	CUI Jian, CHEN Ye, HE Li, BAO Ying, DONG Shaojuan, ZHU Danxia, WU Jun, CUI Mengying. Involvement of the fatty acid metabolism-related gene ACSL1 in acute myeloid leukemia [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(4): 298-304.
[15]	SHU Xingmei, SHI Xiaoqian, LIU Yan, LI Dan. Expression of ribosomal protein S6K1 and its regulation on malignant phenotypes in breast cancer cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(3): 179-186,223.